NL-OMON24544尚未招募不适用
Third population-based immune surveillance study for the evaluation of the National Immunisation Programme in the Netherlands: the PIENTER3 study
ational Institute for Public Health and the Environment (RIVM)0 个研究点目标入组 8,400 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 8,400
研究概览
简要总结
Van der Klis FR, Mollema L, Berbers GA, de Melker HE, Coutinho RA. Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med. 2009 Jul-Aug;67(7):301-8.
Mollema L, de Melker HE, Hahné SJM, van Weert JWM, Berbers GAM, van der Klis FRM. PIENTER 2 project: second research project on the protection against infectious diseases offered by the national immunization programme in the Netherlands. RIVM report 230421001/2009.
PIENTER2 study 2006-2007: A summary of the main findings. Van der Klis FRM, Mollema L, van Weert JWM. RIVM report, April 2012.
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Subject is part of the national study sample drawn from the population register, aged 0 to 89 year old and has received a personal invitation for the PIENTER study.
- •Subject has given written Informed Consent (IC) before the start of the study visit.
排除标准
- 未提供
研究者
相似试验
招募中
不适用
Immunity against SARS-CoV-2 in Dutch populatio<p>COVID-19, SARS-CoV-2</p>NL-OMON21435ational Institute for Public Health and the Environment (RIVM)14,000
已完成
不适用
Third population-based immune surveillance study used for the evaluation of immunity against SARS-CoV-2COVID-19SARS-CoV-210047438NL-OMON52416RIVM11,229
已完成
不适用
Third population-based immune surveillance study for the evaluation of the National Immunisation Programme in the Netherlands: the PIENTER3 studyimmune systemprotection against infectious diseases10019815NL-OMON42468RIVM8,400
进行中（未招募）
不适用
The health burden of COVID-19 and healthcare resource utilization in EnglandCOVID-19 (SARS-CoV-2 infection)Infections and InfestationsISRCTN53375662AstraZeneca (United Kingdom)11,990,730
已完成
3 期
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of AgeInfluenza, HumanNCT03165617Seqirus4,514